INTRODUCTION
Apocrine malignancies are rare to occur. Apocrine malignancy carries high risk of lymphatic and vascular spreading to lung, liver and bone. [1] [2] [3] Axilla and the anogenital skin is the most common sites o-f primary tumour. Other sites where apocrine malignancies reported are the eyelid, scalp, ear, chest, lip, foot, toe and first finger. Clinically, the tumour starts with non-tender, single or multiple, firm to hard superficial masses with red to purple discolouration. [1] [2] [3] Prognosis of the disease depends on tumour free margins of the resected part of the tumour, tumour size and degree of differentiation.
CASE REPORT
A 40 years old painter by occupation admitted to our hospital with c/o swelling below the left ankle joint for 2 years, progressively patient developed diffuse swelling and pain in the left lower limb up to left inguinal region, throbbing in nature, with painful movement at both ankle and knee joint since 5 to 6 months. 
DISCUSSION
There are two types of sweat glands: eccrine glands and apocrine glands. Eccrine glands do not show cytological changes during secretion and apocrine glands, characterised by decapitation secretion, in which part of the cell is pinched off and released into the lumen. 4 Eccrine glands play a major role in thermoregulation and electrolyte balance. They are present everywhere in the human skin and are composed of a secretory portion, an intradermal duct and an upper intraepidermal part, called acrosyringium.
The acrosyringium has a unique symmetrical and helicoidal course, which length is correlated to the thickness of the epidermis. 4 Apocrine glands are located only on genital, axillary and mammary areas, where they are always connected to a hair follicle. Their exact role in humans is unknown. A third type of intermediate sweat glands, the apoeccrine glands, was recently described in axillary areas. 4 Sweat glands can be involved in various inflammatory processes and can lead to a large range of both benign and malignant tumors. 4, 5 Sweat gland malignancies are the rare. The first report was published in 1944. There are two subtypes mainly eccrine and apocrine gland adenocarcinoma, in world literature it accounts of approximately 200 and 38 cases respectively. Apocrine tumours are much less common than eccrine glands. Apocrine adenocarcinoma also been observed to arise in association with other benign tumours such as apocrine adenoma and Apocrine hyperplasia. 6, 7, 8 It is often clinically diagnosed incorrectly. Mainly diagnosed on histopathological examination of resected specimen, which is again an incidental finding. These neoplasms are both complex and cumbersome. Tumour spread through lymphatic and haematogenous route, most commonly spread to the regional lymph nodes, liver and lungs. At the time of presentation, about one third of the patient presents with involvement of regional lymph node. 7 Microscopically, eccrine and apocrine both have the appearance of adenocarcinoma with PAS (Periodic acid Schiff) because of the presence of glycogen granules. Both can be differentiated on basis of diastase digestion property. 7 Apocrine tumour cells are diastase resistant cells as apocrine tumour cell digests diastase and they retain PAS stain. An eccrine tumour cell is diastase sensitive and does not retain the PAS stain. 7, 9, 10 Treatment choice is wide local excision with adequate tumour free margins. 7, 8 The prognosis of apocrine adenocarcinoma is very poor and its prognosis all depends on size of the tumors, histological type, lymph node involvement and distant metastasis. The disease-free survival rate for 10 years in the absence of metastasis to the lymph nodes is reported to be 56%. This percentage, however, drops to 9% if lymph node metastasis is involved. 9, 10 Various case reports mentioned that transient response to various chemotherapy agents. Bellman et al., described excellent response to systemic 5-fluorouracil chemotherapy by patient with widely metastatic apocrine gland. Two patients with sweat-gland carcinoma well responded to combination chemotherapy with doxorubicin, cyclophosphamide, vincristine, and bleomycin was described by Mezger et al., In one of these patients has achieved complete remission of tumour for 2 years duration; the other patient had a partial remission of tumour for 4 months duration.
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CONCLUSION
Apart from Dermatologists other board specialty consultant should be aware of the possibility of apocrine adenocarcinoma while differentiating cutaneous tumor located in the extremities of the limb.
Apocrine malignancy should be treated aggressively with wide local excision or amputation the involved part for improving the life expectancy. Since prevalence of apocrine malignancy are rare, and it is associated with increased mortality, it provokes us the field of research for discovering other modalities of treatment.
